Loading...
XKRX
017180
Market cap26mUSD
Jul 10, Last price  
1,237.00KRW
1D
1.89%
1Q
-31.66%
Jan 2017
-75.86%
IPO
-53.99%
Name

Myungmoon Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:017180 chart
P/E
21.82
P/S
0.21
EPS
56.70
Div Yield, %
Shrs. gr., 5y
3.01%
Rev. gr., 5y
8.84%
Revenues
195.25b
+4.72%
60,927,940,00077,390,430,00097,191,219,000105,183,289,000125,619,902,280100,538,968,880103,723,479,410105,420,701,980125,100,920,170142,179,739,050140,137,942,910147,498,532,160149,346,276,620127,852,855,900137,759,902,000152,134,940,500169,567,372,990186,443,052,000195,247,097,000
Net income
1.90b
P
6,583,195,0004,863,329,0002,940,981,0003,067,853,0004,554,000,000-12,273,359,0001,025,971,000761,490,080-16,135,460,8406,745,899,0007,807,498,230988,268,550-20,832,841,850-27,753,013,560-6,804,256,8007,867,987,000-4,524,837,260-3,034,504,0001,895,288,000
CFO
-1.70b
L+27.39%
459,089,000-1,718,672,000-4,220,097,0002,870,640,000-1,415,963,4402,780,662,8102,003,532,500-36,233,890-5,504,596,3805,601,082,0508,023,816,12011,407,275,730-2,941,626,920-16,672,465,190854,995,9505,474,842,480-5,180,519,690-1,337,700,000-1,704,078,000
Dividend
Dec 27, 201795.42413 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

MYUNGMOON Pharm Co., Ltd. operates as a pharmaceutical enterprise, comprehensively handling the research, development, production, distribution, and commercialization of medicinal products. Its business activities extend across South Korea and into global markets. The company offers an extensive array of prescription drugs, addressing a broad spectrum of medical conditions. This range includes treatments for musculoskeletal issues like osteoarthritis, inflammation, rheumatoid arthritis, and muscle relaxation, alongside anti-infectives (antibiotics and antifungals), respiratory aids, and gastrointestinal therapeutics. Cardiovascular health is targeted with circulation agents, anti-hypertensive drugs, and antidiabetic medications. Furthermore, their specialized pharmacotherapy solutions cover narcotics, anesthetics, central nervous system agents, female hormone products, osteoporosis treatments, urogenital medications, adrenocortical hormones, oncology drugs, dermal fillers, and anti-obesity agents. Beyond prescription items, MYUNGMOON Pharm also supplies a diverse selection of over-the-counter (OTC) remedies. These encompass medications for nausea, genitourinary concerns, gum disease, liver support, parasitic infections, constipation, oral ailments, diarrhea, and general digestive health. The OTC portfolio further includes cold and flu treatments, calcium supplements, nasal sprays, multi-vitamins, eye nutrition products, eye drops, blood circulation enhancers, and topical preparations such as external skin treatments and localized pain relievers. In addition to its pharmaceutical lines, the firm markets health supplements, quasi-pharmaceuticals, and blended juice beverages. Established in 1983, MYUNGMOON Pharm Co., Ltd. maintains its primary corporate office in Seoul, South Korea.
IPO date
Jul 10, 2008
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT